From DCAT Value Chain Insights (VCI)
Eli Lilly and Company has appointed Levi Garraway, MD, PhD, to the position of senior vice president, global development and medical affairs, for Lilly's oncology business, effective on January 1, 2017. He will succeed Richard Gaynor, MD, who will retire. Dr. Garraway will report to Sue Mahony, PhD, Lilly senior vice president and president of Lilly Oncology.
Dr. Garraway is currently associate professor of medicine in the department of medical oncology at the Dana-Farber Cancer Institute and Harvard Medical School, an associate physician at the Brigham and Women's Hospital, an Institute Member of the Broad Institute of MIT and Harvard, and an investigator of the Howard Hughes Medical Institute. Dr. Garraway's industry activities also include being a founder of Foundation Medicine, a leading company in cancer genomics diagnostics.
Source: Eli Lilly and Company
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription